Sitemap - 2024 - Mission GBM
Breaking News: FDA Approves Vorasidenib (Voranigo®)
Michael Lim, MD – Brain Cancer Science Talk (Episode 7)
The Reality of Clinical Trials – Part 2
ASCO 2024: Brain Cancer Highlights
Anniversary Post: 35 Years, 918 Days…and Counting
David D. Tran, MD, PhD – Brain Cancer Science Talk (Episode 6)
Paul S. Mischel, MD – Brain Cancer Science Talk (Episode 5)
Meet the Team – Paul S. Mischel, MD
News: Erasca Reorganizes and Deprioritizes Development of ERAS-801 for rGBM
Samuel Blackman, MD, PhD – Brain Cancer Science Talk (Episode 4)
John de Groot, MD – Brain Cancer Science Talk (Episode 3)
Meet the Team: Graeme Woodworth, MD
Graeme Woodworth, MD – Brain Cancer Science Talk (Episode 2)
Michael L. Dougan, MD, PhD – Brain Cancer Science Talk (Episode 1)
Coming Soon: Brain Cancer Science Talk Series
Sam Blackman Speaks from the Heart
Breaking News: FDA Approves Tovorafenib (Ojemda®) for Pediatric LGG with BRAF Mutations
The Reality of Clinical Trials - Part 1
Marizomib Fails a Phase 3 Clinical Trial in ndGBM Patients
Novocure Reports METIS Top Line Clinical Trial Results for Brain Metastases from NSCLC
Julie Update: Here Be the Dragons
CAR-Ts and GBM: A Long Way Yet to Go
FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-mutant Diffuse Glioma
Investing in Brain Cancer – Part 5
Investing in Brain Cancer - Part 4
Another EGFRvIII-targeted Program BiTEs the Dust
Investing in Brain Cancer - Part 3b
Investing in Brain Cancer - Part 3a
Investing in Brain Cancer - Part 2
MimiVax Announces New Investments to Support Clinical Development of SurVaxM in Glioblastoma